TOKYO, Japan & MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the European Medicines Agency (EMA) has validated the Type II ...
This is the first of five chapters that comprise Part IV of the book. These chapters demonstrate RMM as a platform for empirical modeling of random variation. The claim of RMM for a "universal" ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results